Immunic Showcases Research on Chronic Inflammatory Diseases at Key International Conferences

Immunic Advances Research on Chronic Inflammatory Diseases at Key Conferences

Immunic, Inc., a biotechnology company focused on innovative treatments for chronic inflammatory and autoimmune diseases, is set to make significant contributions to the scientific community this October. The firm participates in several prestigious conferences, where it showcases its research advancements and engages with industry stakeholders. One of the highlights is the United European Gastroenterology Week (UEGW) in Berlin from October 4-7, where Immunic presents data on its promising candidate, IMU-856. This epigenetic modulator, which targets SIRT6, demonstrates positive effects on gut hormone levels in patients with celiac disease, as evidenced by a Phase 1 clinical study. The oral presentation on October 6, led by Dr. Amelie Schreieck, is anticipated to draw considerable attention from gastroenterology experts.

In addition to the UEGW, Immunic participates in the 17th International Congress of the International Society of Neuroimmunology in Chiba, Japan, from October 5-8. Here, the company highlights its lead asset, vidofludimus calcium (IMU-838), which shows neuroprotective effects in preclinical models. Dr. Evelyn Peelen presents key findings on October 7, further establishing Immunic's commitment to understanding and addressing neuroinflammatory conditions. This dual presence at significant international conferences underscores Immunic's strategic focus on both gastrointestinal and neuroimmunological disorders, showcasing the breadth of its research portfolio.

These presentations not only reflect Immunic's dedication to advancing scientific knowledge but also serve to enhance its visibility within the biotechnology sector. The company plans to make all relevant materials available on its website, allowing interested parties to access findings and data. Furthermore, the company's participation in the Roth's 4th Annual Healthcare Opportunities Conference in New York on October 9, where CEO Daniel Vitt and CFO Glenn Whaley engage in a panel discussion, indicates a proactive approach to fostering investor relations and promoting dialogue on future developments in the biotech field.

In summary, Immunic's active involvement in these critical conferences highlights its ongoing commitment to pioneering research and its role in the biotechnology landscape. By presenting groundbreaking data on its therapeutic candidates, Immunic positions itself as a leader in developing treatments for chronic inflammatory diseases, aiming to improve patient outcomes and contribute to the broader medical community.